Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is OptumRx prior authorization process?
OptumRx is the pharmacy benefit management (PBM) arm of UnitedHealth Group. It manages drug formularies, processes pharmacy claims, and administers utilization management programs for UnitedHealthcare commercial plans, Medicare Part D, Medicaid managed care, and employer-sponsored benefits.
How the OptumRx Prior Authorization Process Works (Step-by-Step)
Phase 1: Identification and Submission
| Item | Details |
|---|---|
| Trigger: | A prescription is rejected at the pharmacy with a “PA Required” message. The pharmacy notifies the prescriber’s office |
| Check formulary status: | Verify the drug’s tier and PA requirement on the OptumRx formulary at professionals.optumrx.com or by calling 800-711-4555 |
| Gather documentation: | Collect diagnosis codes (ICD-10), relevant lab results, medication history, prescriber rationale, and any prior trial-and-fail records for step therapy drugs |
| Submit the PA request: | Choose one of three submission channels: |
Phase 2: Review and Decision
| Reason | How to Fix |
|---|---|
| Clinical review: | OptumRx clinical pharmacists or medical directors review the request against drug-specific PA criteria. This includes checking FDA-approved indications, plan formulary rules, step therapy requirements, and quantity limits |
| Decision: | OptumRx typically processes PA decisions within 24 hours of receiving complete documentation. By law, urgent requests must be decided within 72 hours and standard requests within 7 calendar days (per CMS-0057-F, effective January 2026) |
| Notification: | The prescriber and patient receive written notification of the decision. Approvals include the duration (usually 6-12 months). Denials include the specific reason and appeal instructions |
Key point: Incomplete submissions are the primary cause of delays. Include all required clinical documentation in the initial request to avoid back-and-forth.
OptumRx Formulary Tiers and PA Criteria
OptumRx organizes covered medications into formulary tiers based on cost and clinical preference:
PA criteria vary by drug class but typically include: – Confirmed diagnosis with ICD-10 code matching an FDA-approved indication – Documentation that the patient tried and failed preferred formulary alternatives (step therapy) – Lab results supporting the clinical need (e.g., HbA1c for diabetes medications, lipid panels for specialty statins) – Prescriber specialization when required (e.g., oncologist for oncology drugs, endocrinologist for growth hormones) – Quantity within plan-defined limits
Step therapy explained: OptumRx may require patients to try a lower-cost “step 1” medication before covering a “step 2” alternative. If the patient has not tried the preferred drug recently, the prescriber must submit evidence of prior trial-and-fail or request a clinical exception. For payer-specific help building these requests, see our step therapy override support.
Stat: MGMA’s 2025 PA Report identifies PA as the top administrative burden for medical group practices, with the highest impact on Medicare Advantage plans (MGMA 2025).
Common Drug Classes Requiring OptumRx Prior Authorization
Based on OptumRx formulary data and utilization management updates (2025-2026):
Phase 1: High-Volume PA Categories
- GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) for diabetes and weight management
- Specialty biologics (Humira, Enbrel, Stelara, Dupixent) for autoimmune conditions
- Oncology drugs (oral chemotherapy agents, targeted therapies)
- HIV/hepatitis C antivirals
- Growth hormones (Norditropin, Genotropin, Humatrope)
Phase 2: Expanding PA Categories
- PCSK9 inhibitors (Repatha, Praluent) for high cholesterol
- CGRP inhibitors (Aimovig, Ajovy, Emgality) for migraine prevention
- JAK inhibitors (Xeljanz, Rinvoq, Olumiant) for rheumatoid arthritis
- ADHD medications (certain extended-release formulations)
- Controlled substances above quantity thresholds
2026 Update: OptumRx eliminated reauthorizations for roughly 80 drugs in May 2025 and added 40 more in January 2026. Drug classes affected include chronic condition medications, hormone therapy, and knee osteoarthritis injectables (Source: Healthcare Dive, UHG Newsroom).
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Top OptumRx PA Denial Reasons and How to Fix Them
1. Incomplete clinical documentation The most common denial reason. The PA request was missing diagnosis codes, lab values, or medication history that OptumRx needs to apply clinical criteria. – Fix: Submit all supporting records with the initial request. Use the OptumRx drug-specific PA form (available at professionals.optumrx.com) to confirm exactly which fields are required.
2. Step therapy not completed The prescribed drug is a “step 2” medication, and the patient has no documented trial-and-fail of the preferred “step 1” alternative. – Fix: Document why the step 1 drug is clinically inappropriate (allergy, contraindication, prior adverse reaction, documented failure). Submit the exception request with supporting evidence.
3. Off-label use without supporting evidence The prescribed drug is being used for a condition outside its FDA-approved indications, and the PA request did not include peer-reviewed evidence or compendia support. – Fix: Include published clinical evidence (peer-reviewed studies, NCCN Compendium, AHFS) supporting the off-label use alongside the PA form.
4. Non-formulary drug without exception justification The drug is not on the patient’s OptumRx formulary, and no formulary exception request was submitted. – Fix: Submit a formulary exception request with clinical rationale explaining why no formulary alternative is appropriate for this patient.
5. Expired or lapsed prior authorization A previously approved PA expired, and a new PA was not submitted before the refill window. – Fix: Track PA expiration dates proactively. Set calendar reminders 30 days before expiration. Note that OptumRx eliminated reauthorization requirements for 120+ drugs in 2025-2026, so check current requirements before resubmitting.
Stat: The AMA reports 61% of physicians believe payers’ use of AI is increasing denial rates (AMA 2025 Survey Update).
The OptumRx PA Appeal Process
When a PA is denied, providers have multiple paths to overturn the decision:
Standard Appeal:
| Item | Details |
|---|---|
| Fax: | 844-403-1027 (non-urgent) |
| Electronic: | Through the ePA portal or CoverMyMeds |
| Turnaround: | 24-48 hours for appeal review. After 48 hours, call 866-441-2422 for status |
Medicare Part D Redetermination:
- Members have 60 days from the denial notice to file a redetermination
- If the redetermination is upheld, the next level is an Independent Review Entity (IRE) appeal
- Expedited review available for urgent clinical situations
Appeal documentation tips:
- Include any new clinical information not in the original PA request
- Attach a letter of medical necessity from the prescriber
- Reference specific clinical criteria from OptumRx guidelines showing the patient meets approval requirements
- If denied for step therapy, document why the preferred alternative is not clinically appropriate for this patient
Peer-to-peer review: Prescribers can request a peer-to-peer phone consultation with the OptumRx medical director who reviewed the case. This is often the fastest path to overturning a clinical denial.
OptumRx PA in State Medicaid Programs (GA, PA, IL)
Georgia Georgia’s Medicaid FFS pharmacy program uses OptumRx as its PBM. The Department of Community Health (DCH) sets all PA criteria, published by therapeutic class at dch.georgia.gov.
Key details: – PA criteria are set by DCH, not OptumRx. OptumRx administers the process – Georgia Medicaid MCOs (CareSource GA, Peach State, Amerigroup) maintain separate formularies and PA portals – Providers can call 800-711-4555 to request drug-specific PA guidelines – The FFS PA process guide is available at dch.georgia.gov/providers/provider-types/pharmacy
Pennsylvania PA DHS maintains a Statewide Preferred Drug List covering both FFS and HealthChoices MCOs. Non-preferred drugs require PA to confirm medical necessity.
Key details: – The DHS Covered Drug Search tool (humanservices.dhs.pa.gov) shows PA requirements, quantity limits, and copay information for specific drugs – HealthChoices beneficiary PAs route to the assigned MCO (AmeriHealth Caritas, UPMC Health Plan, Highmark Wholecare, Aetna Better Health) – Effective January 2026, PA DHS no longer approves GLP-1 PAs for overweight/obesity-only indications under Medicaid – PA clinical guidelines published on the DHS Pharmacy Services page
Illinois Illinois HFS maintains a Medicaid Preferred Drug List (updated January 27, 2026) with drug-specific PA requirements.
Key details: – PA submissions accepted via NCPDP D.0 electronic format, fax (217-524-7264), or phone (800-252-8942) – The ilpriorauth.com drug search tool shows PA requirements, quantity limits, and formulary status – Illinois Medicaid MCOs (Meridian, Molina, CountyCare, Blue Cross Community) maintain separate formularies – HFS Drug Prior Approval criteria published at hfs.illinois.gov/medicalproviders/pharmacy
Cross-state insight: Providers managing OptumRx PAs across multiple states must track both the plan-level PA criteria (set by OptumRx or the MCO) and the state Medicaid PA criteria (set by the state agency). These are not always the same.
What most OptumRx PA guides politely skip: The May 2025 and January 2026 reauthorization-elimination lists are a gift most practices still have not claimed. OptumRx quietly removed reauthorization requirements for 120+ drugs over the past year, including common chronic condition medications, but the information is buried in bulletins and newsroom announcements. Your staff may still be preparing reauth paperwork for drugs that no longer need it. Before you submit another reauth, pull the current OptumRx “reauthorization not required” list and scrub your active patient panel against it. Practices that did this audit once in early 2026 eliminated 15-20% of their OptumRx PA volume overnight. The ones that did not are still paying staff to do reauth work the PBM no longer requires, because nobody told them the rule changed. Calendar quarterly checks of UHG newsroom PA updates into your workflow.
Why Practices Outsource OptumRx Prior Authorization
The math is straightforward. The AMA reports that the average practice spends 12 staff hours per physician per week on prior authorizations across all payers. For a 5-physician practice, that is 60 hours per week, or 1.5 full-time employees dedicated to PA paperwork.
The cost problem:
- U.S.-based PA coordinator salary: $38,000-$52,000/year (BLS, 2025)
- Fully loaded cost with benefits, training, and turnover: $55,000-$75,000/year
- Staffingly PA specialist: $399/week (volume discounts to $299/week), fully trained, no benefits overhead
What outsourced PA teams handle:
- Formulary lookup and PA requirement confirmation
- Clinical documentation gathering and PA form completion
- Electronic submission through CoverMyMeds and payer portals
- Denial management and appeal submission
- Reauthorization tracking and proactive resubmission
Stat: The CAQH 2024 Index estimates PA costs the U.S. healthcare industry $35 billion annually in administrative spending. McKinsey reports that outsourcing and automation can reduce these operational costs by up to 30% (CAQH 2024; McKinsey Healthcare Operations Report).
How Staffingly Handles OptumRx Prior Authorizations
Staffingly deploys trained PA specialists who work directly inside your EHR and payer portals. The team handles Optum and OptumRx prior authorizations across commercial, Medicare Part D, and Medicaid managed care plans.
What sets Staffingly apart
- 800+ providers served with a 99.2% clean claim rate across all services
- $399/week (volume discounts to $299/week) for PA specialists trained on OptumRx workflows, CoverMyMeds, and 50+ EHR systems
- 48-72 hour go-live from signed agreement to working PA specialist in your workflow
- 70% cost savings compared to hiring in-house PA coordinators
- SOC 2 Type II, HITRUST, ISO 27001, HIPAA compliant operations. Low cost does not mean low security: all operations are HITRUST-mapped, SOC 2 Type II certified, and HIPAA-compliant
- 15-Day Risk-Free Pilot to validate results before any long-term commitment
How We Achieve These Results:
- AI Pre-Scrubbing: Every PA request is checked against payer-specific criteria before submission, catching missing documentation before it triggers a denial
- Multi-Layer Human QA: Clinical reviewers verify diagnosis codes, step therapy compliance, and documentation completeness
- Real-Time AR Tracking: PA status dashboards give your team visibility into every pending, approved, and denied request
Book a Strategy Call to see how Staffingly’s PA team can reduce your OptumRx authorization backlog.
FAQs
Q: What is the OptumRx prior authorization phone number? A: Call 866-434-5524 for PA submissions and status checks. For denial discussions and appeals, call 800-711-4555 (Mon-Fri 5am-10pm PT, Sat 6am-3pm PT).
Q: What is the OptumRx PA fax number? A: The primary PA fax is 866-434-5523. However, OptumRx is retiring most fax numbers and directing providers to electronic PA submission through CoverMyMeds or the ePA portal at professionals.optumrx.com.
Q: How long does an OptumRx prior authorization take? A: OptumRx typically processes PA decisions within 24 hours of receiving complete documentation. By federal rule (CMS-0057-F, effective January 2026), urgent requests must be decided within 72 hours and standard requests within 7 calendar days.
Q: What do I do if OptumRx denies my prior authorization? A: You can appeal by phone (800-711-4555), fax (844-403-1027), or electronically. Include any new clinical documentation not in the original submission. Appeal reviews take 24-48 hours. For Medicare Part D, you have 60 days to file a redetermination.
Q: Does OptumRx use step therapy? A: Yes. Step therapy requires the patient to try a lower-cost preferred medication before OptumRx covers a higher-cost alternative. If the step 1 drug is clinically inappropriate, submit a step therapy exception with documented rationale.
Q: What is the difference between OptumRx and UnitedHealthcare for PA purposes? A: UnitedHealthcare is the health insurer. OptumRx is the pharmacy benefit manager (PBM) that administers the drug formulary, PA process, and pharmacy claims on behalf of UnitedHealthcare plans.
Q: Can I submit an OptumRx PA electronically? A: Yes. Electronic PA (ePA) is available through CoverMyMeds (go.covermymeds.com/optumrx) and the OptumRx professionals portal. Electronic submission is faster and provides tracking confirmation.
Q: Does Georgia Medicaid use OptumRx? A: Yes. OptumRx serves as the PBM for Georgia Medicaid Fee-for-Service. PA criteria are set by the Department of Community Health (DCH), not OptumRx. Georgia Medicaid MCOs use separate PA processes.
Q: How much does it cost to outsource OptumRx prior authorizations? A: Staffingly’s PA specialists start at $399/week (volume discounts to $299/week) with a 15-Day Risk-Free Pilot, compared with a fully loaded in-house PA coordinator cost of $55,000-$75,000 per year.
